{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:21:29Z","timestamp":1793740889478,"version":"4.6.1"},"reference-count":153,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"vor","delay-in-days":224,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.neuropharm.2022.109220","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T14:40:11Z","timestamp":1660747211000},"page":"109220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling"],"prefix":"10.1016","volume":"218","author":[{"given":"Jack E.","family":"Henningfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion A.","family":"Coe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland R.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean J.","family":"Belouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison R.","family":"Coker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra D.","family":"Comer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Heal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Hendricks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles D.","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Sapienza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank J.","family":"Vocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah Z.","family":"Zia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.neuropharm.2022.109220_bib1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/0046760X.2014.979251","article-title":"From recreational to functional drug use: the evolution of drugs in American higher education","volume":"44","author":"Aikins","year":"2015","journal-title":"Hist. Educ."},{"issue":"12","key":"10.1016\/j.neuropharm.2022.109220_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207820","article-title":"The national Institutes of health measure of healing experience of all life stressors (NIH-HEALS): factor analysis and validation","volume":"13","author":"Ameli","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2022.109220_bib3","series-title":"Diagnostic and Statistical Manual of Mental Disorders : DSM-5","year":"2013"},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109220_bib4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12954-019-0308-4","article-title":"Psychedelic microdosing benefits and challenges: an empirical codebook","volume":"16","author":"Anderson","year":"2019","journal-title":"Harm Reduct. J."},{"key":"10.1016\/j.neuropharm.2022.109220_bib5","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.1476-5381.2012.02214.x","article-title":"Use of intracranial self-stimulation to evaluate abuse-related and abuse-limiting effects of monoamine releasers in rats","volume":"168","author":"Bauer","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109220_bib6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/7854_2016_53","article-title":"Neuropharmacology of 3,4-methylenedioxypyrovalerone (MDPV), its metabolites, and related analogs","volume":"32","author":"Baumann","year":"2017","journal-title":"Curr. Top Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109220_bib7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/164_2018_178","article-title":"Neuropharmacology of synthetic cathinones","volume":"252","author":"Baumann","year":"2018","journal-title":"Handb. Exp. Pharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109220_bib8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0376-8716(86)90047-5","article-title":"Self-administration of methylenedioxymethamphetamine (MDMA) by rhesus monkeys","volume":"18","author":"Beardsley","year":"1986","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2022.109220_bib9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.neuropharm.2018.02.018","article-title":"Psychedelics: where we are now, why we got here, what we must do","volume":"142","author":"Belouin","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109220_bib10","author":"Belouin","year":"2022","journal-title":"Policy considerations that support safe, ethical, accountable, and equitable uses of psychedelic medicines. Neuropharmacology"},{"issue":"11","key":"10.1016\/j.neuropharm.2022.109220_bib11","first-page":"966","article-title":"The origin of MDMA (\"ecstasy\")--separating the facts from the myth","volume":"61","author":"Bernschneider-Reif","year":"2006","journal-title":"Pharmazie"},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109220_bib12","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00213-017-4777-4","article-title":"Regulation of human research with LSD in the United States (1949-1987)","volume":"235","author":"Bonson","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2022.109220_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.735427","article-title":"Self-medication for chronic pain using classic psychedelics: a qualitative investigation to inform future research","volume":"12","author":"Bornemann","year":"2021","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109220_bib14","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.mayocp.2014.09.003","article-title":"Mitigating the safety risks of drugs with a focus on opioids: are risk evaluation and mitigation strategies the answer?","volume":"89","author":"Brooks","year":"2014","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.neuropharm.2022.109220_bib16","series-title":"Regulatory Framework and Guidance to the Evaluation of the Abuse Liability of Drugs in the United States and Europe. Nonclinical Assessment of Abuse Potential for New Pharmaceuticals","first-page":"245","author":"Calderon","year":"2015"},{"key":"10.1016\/j.neuropharm.2022.109220_bib15","unstructured":"Calderon, S.N., 2022, (In this issue). TBA."},{"key":"10.1016\/j.neuropharm.2022.109220_bib17","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.neuropharm.2017.11.028","article-title":"A regulatory perspective on the evaluation of hallucinogen drugs for human use","volume":"142","author":"Calderon","year":"2018","journal-title":"Neuropharmacology"},{"issue":"12","key":"10.1016\/j.neuropharm.2022.109220_bib18","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1177\/0269881116662634","article-title":"Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences","volume":"30","author":"Carbonaro","year":"2016","journal-title":"J. Psychopharmacol."},{"issue":"8","key":"10.1016\/j.neuropharm.2022.109220_bib19","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1007\/s00213-020-05533-9","article-title":"Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan","volume":"237","author":"Carbonaro","year":"2020","journal-title":"Psychopharmacology (Berl)"},{"issue":"11","key":"10.1016\/j.neuropharm.2022.109220_bib20","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/npp.2017.84","article-title":"The therapeutic potential of psychedelic drugs: past, present, and future","volume":"42","author":"Carhart-Harris","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2022.109220_bib21","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.drugalcdep.2009.04.003","article-title":"Principles of laboratory assessment of drug abuse liability and implications for clinical development","volume":"105","author":"Carter","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2022.109220_bib22","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/pm\/pnw129","article-title":"ER\/LA opioid analgesics REMS: overview of ongoing assessments of its progress and its impact on health outcomes","volume":"18","author":"Cepeda","year":"2017","journal-title":"Pain Med."},{"key":"10.1016\/j.neuropharm.2022.109220_bib23","series-title":"Making MDMA a Medicine: Analysis of the 8-factors of the Controlled Substances Act for the Abuse Potential of MDMA","author":"Coker","year":"2021"},{"key":"10.1016\/j.neuropharm.2022.109220_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108530","article-title":"Potential unintended consequences of class-wide drug scheduling based on chemical structure: a cautionary tale for fentanyl-related compounds","volume":"221","author":"Comer","year":"2021","journal-title":"Drug Alcohol Depend."},{"issue":"58","key":"10.1016\/j.neuropharm.2022.109220_bib27","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/jncimonographs\/lgab009","article-title":"Challenges for clinical cannabis and cannabinoid research in the United States","volume":"2021","author":"Cooper","year":"2021","journal-title":"J. Natl. Cancer Inst. Monogr."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109220_bib28","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00213-017-4822-3","article-title":"Psychedelics and related drugs: therapeutic possibilities, mechanisms and regulation","volume":"235","author":"Curran","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109220_bib29","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0376-8716(91)90054-3","article-title":"Testing the abuse liability of anxiolytic and hypnotic drugs in humans","volume":"28","author":"de Wit","year":"1991","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2022.109220_bib30","author":"Dworkin","year":"2022","journal-title":"If the doors of perception were cleansed, would chronic pain be relieved? Evaluating the benefits and risks of psychedelics. J Pain"},{"issue":"3 Suppl. l","key":"10.1016\/j.neuropharm.2022.109220_bib31","first-page":"S107","article-title":"Abuse liability assessment of CNS drugs: conclusions, recommendations, and research priorities","volume":"70","year":"2003","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109220_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1037\/1064-1297.16.1.1","article-title":"In vivo pharmacology of MDMA and its enantiomers in rhesus monkeys","volume":"16","author":"Fantegrossi","year":"2008","journal-title":"Exp. Clin. Psychopharmacol"},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109220_bib33","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s00213-002-1021-6","article-title":"3,4-Methylenedioxymethamphetamine (MDMA, \"ecstasy\") and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement","volume":"161","author":"Fantegrossi","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109220_bib34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.bcp.2007.07.018","article-title":"The behavioral pharmacology of hallucinogens","volume":"75","author":"Fantegrossi","year":"2008","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109220_bib169","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00008877-200403000-00007","article-title":"Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys","volume":"15","author":"Fantegrossi","year":"2004","journal-title":"Behav. Pharmacol."},{"issue":"9","key":"10.1016\/j.neuropharm.2022.109220_bib35","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/j.1360-0443.2006.01511.x","article-title":"The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents","volume":"101","author":"Freudenmann","year":"2006","journal-title":"Addiction"},{"key":"10.1016\/j.neuropharm.2022.109220_bib36","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.vascn.2019.02.008","article-title":"FOB vs modified Irwin: what are we doing?","volume":"97","author":"Gauvin","year":"2019","journal-title":"J. Pharmacol. Toxicol. Methods"},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109220_bib37","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/med.2610030305","article-title":"Drug-induced discrimination: a description of the paradigm and a review of its specific application to the study of hallucinogenic agents","volume":"3","author":"Glennon","year":"1983","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.neuropharm.2022.109220_bib38","first-page":"18","article-title":"Marihuana, LSD, and amphetamines","volume":"5","author":"Gorodetzky","year":"1970","journal-title":"Drug Depend."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109220_bib39","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/BF00404013","article-title":"A comparison of 2,3-dihydro-lysergic acid diethylamide with LSD-25","volume":"6","author":"Gorodetzky","year":"1964","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.neuropharm.2022.109220_bib40","series-title":"Similarities in Animal and Human Drug Taking Behavior. Advances in Substance Abuse: Behavioral and Biochemical Research","first-page":"1","author":"Griffiths","year":"1980"},{"issue":"3 Suppl. l","key":"10.1016\/j.neuropharm.2022.109220_bib41","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S0376-8716(03)00098-X","article-title":"Principles of initial experimental drug abuse liability assessment in humans","volume":"70","author":"Griffiths","year":"2003","journal-title":"Drug Alcohol Depend."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109220_bib42","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance","volume":"187","author":"Griffiths","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"issue":"12","key":"10.1016\/j.neuropharm.2022.109220_bib43","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109220_bib44","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/0269881117731279","article-title":"Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors","volume":"32","author":"Griffiths","year":"2018","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109220_bib45","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1176\/appi.psychotherapy.1986.40.3.393","article-title":"Can drugs be used to enhance the psychotherapeutic process?","volume":"40","author":"Grinspoon","year":"1986","journal-title":"Am. J. Psychother."},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2022.109220_bib46","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.drugalcdep.2006.02.008","article-title":"Impact of formulation on the abuse liability, safety and regulation of medications: the expert panel report","volume":"83","author":"Grudzinskas","year":"2006","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2022.109220_bib47","article-title":"Psychedelics, placebo effects, and set and setting: insights from common factors theory of psychotherapy","volume":"1363461520983684","author":"Gukasyan","year":"2021","journal-title":"Transcult. Psychiatr."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109220_bib48","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2466\/pr0.1964.14.2.483","article-title":"On the Addiction Research Center Inventory scores of former addicts receiving LSD and untreated schizophrenics","volume":"14","author":"Haertzen","year":"1964","journal-title":"Psychol. Rep."},{"key":"10.1016\/j.neuropharm.2022.109220_bib49","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/00005053-196504000-00004","article-title":"Subjective drug effects: a factorial representation of subjective drug effects on the Addiction Research Center Inventory","volume":"140","author":"Haertzen","year":"1965","journal-title":"J. Nerv. Ment. Dis."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109220_bib50","first-page":"27","article-title":"Changes in correlation between responses to items of the addiction research center inventory produced by LSD-25","volume":"1","author":"Haertzen","year":"1966","journal-title":"J. Psycho. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109220_bib51","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2466\/pr0.1966.18.1.163","article-title":"Development of scales based on patterns of drug effects, using the Addiction Research Center Inventory (ARCI)","volume":"18","author":"Haertzen","year":"1966","journal-title":"Psychol. Rep."},{"key":"10.1016\/j.neuropharm.2022.109220_bib52","series-title":"Addiction Research Center Inventory (ARCI): Measurement of Euphoria and Other Drug Effects. Methods of Assessing the Reinforcing Properties of Abused Drugs M. A. Bozarth","first-page":"489","author":"Haertzen","year":"1987"},{"key":"10.1016\/j.neuropharm.2022.109220_bib53","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/1097-4679(196310)19:4<407::AID-JCLP2270190410>3.0.CO;2-N","article-title":"Assessing subjective effects of drugs: an index of carelessness and confusion for use with the addiction research center inventor (ARCI)","volume":"19","author":"Haertzen","year":"1963","journal-title":"J. Clin. Psychol."},{"key":"10.1016\/j.neuropharm.2022.109220_bib170","first-page":"843","volume":"31","author":"Halberstadt","year":"2020"},{"key":"10.1016\/j.neuropharm.2022.109220_bib54","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.neuropharm.2018.01.049","article-title":"Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans","volume":"142","author":"Heal","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109220_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuropharm.2018.08.024","article-title":"Psychedelics - re-opening the doors of perception","volume":"142","author":"Heal","year":"2018","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109220_bib56","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1037\/0278-6133.23.1.3","article-title":"Psychological and physical adjustment to breast cancer over 4 years: identifying distinct trajectories of change","volume":"23","author":"Helgeson","year":"2004","journal-title":"Health Psychol."},{"key":"10.1016\/j.neuropharm.2022.109220_bib57","unstructured":"Hendricks, P.S., 2022, (In this issue). TBA."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109220_bib58","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1177\/0269881114565653","article-title":"Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population","volume":"29","author":"Hendricks","year":"2015","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109220_bib59","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/0269881117735685","article-title":"The relationships of classic psychedelic use with criminal behavior in the United States adult population","volume":"32","author":"Hendricks","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109220_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2019.105852","article-title":"The nexus of opioids, pain, and addiction: challenges and solutions","volume":"128","author":"Henningfield","year":"2019","journal-title":"Prev. Med."},{"key":"10.1016\/j.neuropharm.2022.109220_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.775073","article-title":"Kratom abuse potential 2021: an updated eight factor analysis","volume":"12","author":"Henningfield","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109220_bib62","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/BF02584089","article-title":"The addiction research center inventory: standardization of scales which evaluate subjective effects of morphine, amphetamine, pentobarbital, alcohol, LSD-25, pyrahexyl and chlorpromazine","volume":"4","author":"Hill","year":"1963","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.neuropharm.2022.109220_bib63","series-title":"LSD, My Problem Child: Reflections on Sacred Drugs, Mysticism, and Science","author":"Hofmann","year":"1992"},{"issue":"6","key":"10.1016\/j.neuropharm.2022.109220_bib64","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41386-022-01297-2","article-title":"Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects","volume":"47","author":"Holze","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109220_bib65","series-title":"Relieving Pain in America: a Blueprint for Transforming Prevention, Care, Education, and Research. Committee on Advancing Pain Research, Care, and Education","year":"2011"},{"key":"10.1016\/j.neuropharm.2022.109220_bib67","series-title":"The Report of the International Narcotics Control Board for 2021","year":"2021"},{"key":"10.1016\/j.neuropharm.2022.109220_bib68","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF00408109","article-title":"Comparison of the reactions induced by psilocybin and LSD-25 in man","volume":"1","author":"Isbell","year":"1959","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.neuropharm.2022.109220_bib69","series-title":"Effects of Various Drugs on the LSD Reaction. Psychopharmacology Frontiers","first-page":"362","author":"Isbell","year":"1959"},{"issue":"5","key":"10.1016\/j.neuropharm.2022.109220_bib70","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/BF00453511","article-title":"Effect of alkaloids of ololiuqui in man","volume":"8","author":"Isbell","year":"1966","journal-title":"Psychopharmacologia"},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109220_bib71","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/BF00403684","article-title":"A comparison of LSD-25 with (-)-delta-9-trans-tetrahydrocannabinol (THC) and attempted cross tolerance between LSD and THC","volume":"14","author":"Isbell","year":"1969","journal-title":"Psychopharmacologia"},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109220_bib72","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1001\/archneurpsyc.1959.02340130040003","article-title":"Studies on lysergic acid diethylamide (LSD-25). III. Attempts to attenuate the LSD-reaction in man by pretreatment with neurohumoral blocking agents","volume":"81","author":"Isbell","year":"1959","journal-title":"AMA Arch. Neurol. Psychiatry"},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109220_bib73","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/BF00401256","article-title":"Effects of (--)delta-9-trans-tetrahydrocannabinol in man","volume":"11","author":"Isbell","year":"1967","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.neuropharm.2022.109220_bib74","author":"Jaeger"},{"key":"10.1016\/j.neuropharm.2022.109220_bib75","author":"Jaeger"},{"key":"10.1016\/j.neuropharm.2022.109220_bib76","author":"Janssen Research & Development"},{"key":"10.1016\/j.neuropharm.2022.109220_bib77","first-page":"73","article-title":"Human abuse liability assessment by measurement of subjective and physiological effects","volume":"92","author":"Jasinski","year":"1989","journal-title":"NIDA Res. Monogr."},{"key":"10.1016\/j.neuropharm.2022.109220_bib78","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/0165-6147(84)90415-2","article-title":"Abuse liability assessment in human subjects","volume":"5","author":"Jasinski","year":"1984","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109220_bib79","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2174\/18744737112059990005","article-title":"Can MDMA play a role in the treatment of substance abuse?","volume":"6","author":"Jerome","year":"2013","journal-title":"Curr. Drug Abuse Rev."},{"issue":"6","key":"10.1016\/j.neuropharm.2022.109220_bib80","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety","volume":"22","author":"Johnson","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109220_bib81","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","article-title":"The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act","volume":"142","author":"Johnson","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109220_bib82","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pharmthera.2018.11.010","article-title":"Classic psychedelics: an integrative review of epidemiology, therapeutics, mystical experience, and brain network function","volume":"197","author":"Johnson","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2022.109220_bib83","series-title":"Monitoring the Future National Survey Results on Drug Use 1975-2021: Overview, Key Findings on Adolescent Drug Use","author":"Johnston","year":"2022"},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109220_bib84","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/02698811211066714","article-title":"Lifetime use of MDMA\/ecstasy and psilocybin is associated with reduced odds of major depressive episodes","volume":"36","author":"Jones","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109220_bib85","series-title":"A Place of Healing: Working with Suffering in Living and Dying","author":"Kearney","year":"2000"},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109220_bib86","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/BF00518175","article-title":"Self-injection of d,1-3,4-methylenedioxymethamphetamine (MDMA) in the baboon","volume":"91","author":"Lamb","year":"1987","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2022.109220_bib87","author":"Lampe"},{"issue":"27","key":"10.1016\/j.neuropharm.2022.109220_bib88","article-title":"Self-inflicted neck wounds under influence of lysergic acid diethylamide: a case report and literature review","volume":"99","author":"Le Dare","year":"2020","journal-title":"Medicine (Baltim.)"},{"issue":"6","key":"10.1016\/j.neuropharm.2022.109220_bib89","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00005053-196312000-00007","article-title":"Reactions to psilocybin administered in a supportive environment","volume":"137","author":"Leary","year":"1963","journal-title":"J. Nerv. Ment. Dis."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109220_bib90","doi-asserted-by":"crossref","first-page":"fcz025","DOI":"10.1093\/braincomms\/fcz025","article-title":"Dependence, withdrawal and rebound of CNS drugs: an update and regulatory considerations for new drugs development","volume":"1","author":"Lerner","year":"2019","journal-title":"Brain Commun."},{"key":"10.1016\/j.neuropharm.2022.109220_bib91","article-title":"A call to integrate psychedelic science, contemplative practices, and traditional and indigenous knowledge systems into global public health","author":"Magar","year":"2022","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109220_bib92","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0269881114568040","article-title":"Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences?","volume":"29","author":"Majic","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109220_bib93","series-title":"Assessment of the Abuse Potentiality of Amphetamines and LSD-like Hallucinogens in Man and its Relationship to Basic Animal Assessment Programs. Psychic Dependence. Bayer-Symposium","first-page":"146","volume":"vol. 4","author":"Martin","year":"1973"},{"issue":"6","key":"10.1016\/j.neuropharm.2022.109220_bib94","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.explore.2009.10.002","article-title":"The role of mindfulness in healthcare reform: a policy paper","volume":"5","author":"McCabe Ruff","year":"2009","journal-title":"Explore"},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2022.109220_bib95","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.drugalcdep.2009.08.003","article-title":"Case histories in pharmaceutical risk management","volume":"105","author":"McCormick","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2022.109220_bib96","author":"Miller","year":"2019","journal-title":"Research and the DEA Registration. Researcher Conference"},{"key":"10.1016\/j.neuropharm.2022.109220_bib97","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2022.109220_bib98","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3389\/fpsyt.2020.00497","article-title":"Hallucinogens and entactogens: establishing a new class of psychotherapeutic drugs?","volume":"11","author":"M\u00fcller","year":"2020","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109220_bib99","series-title":"An Evidence Review and Research Agenda. Challenges and Barriers in Conducting Cannabis Research. The Health Effects of Cannabis and Cannabinoids: the Current State of Evidence and Recommendations for Research","year":"2017"},{"key":"10.1016\/j.neuropharm.2022.109220_bib103","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1124\/pr.112.007419","article-title":"Intracranial self-stimulation to evaluate abuse potential of drugs","volume":"66","author":"Negus","year":"2014","journal-title":"Pharmacol. Rev."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109220_bib104","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/02791072.1986.10472362","article-title":"Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens","volume":"18","author":"Nichols","year":"1986","journal-title":"J. Psychoact. Drugs"},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109220_bib105","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","article-title":"Hallucinogens","volume":"101","author":"Nichols","year":"2004","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2022.109220_bib106","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.863088","article-title":"Entactogens: how the name for a novel class of psychoactive agents originated","volume":"13","author":"Nichols","year":"2022","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109220_bib107","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.forsciint.2018.01.006","article-title":"Is LSD toxic?","volume":"284","author":"Nichols","year":"2018","journal-title":"Forensic Sci. Int."},{"issue":"8","key":"10.1016\/j.neuropharm.2022.109220_bib108","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrn3530","article-title":"Effects of Schedule I drug laws on neuroscience research and treatment innovation","volume":"14","author":"Nutt","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109220_bib109","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/0269881105048900","article-title":"Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy","volume":"19","author":"Parrott","year":"2005","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109220_bib110","first-page":"105","article-title":"Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users","volume":"60","author":"Parrott","year":"2000","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2022.109220_bib111","doi-asserted-by":"crossref","DOI":"10.1177\/2050324518767442","article-title":"The early use of MDMA (\u2018ecstasy\u2019) in psychotherapy (1977\u20131985)","volume":"4","author":"Passie","year":"2018","journal-title":"Drug Sci. Policy Law"},{"issue":"5","key":"10.1016\/j.neuropharm.2022.109220_bib113","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1177\/0269881117691453","article-title":"The association of psychedelic use and opioid use disorders among illicit users in the United States","volume":"31","author":"Pisano","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109220_bib114","article-title":"Comprehensive drug control bill cleared by congress. CQ Almanac 1970. Washington, DC","volume":"26","author":"Quarterly","year":"1970","journal-title":"Congr. Q."},{"key":"10.1016\/j.neuropharm.2022.109220_bib115","series-title":"Statement of Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control Drug Enforcement Administration before the Caucus on International Narcotics Control United States Senate for a Hearing Entitled \u201cDangerous Synthetic Drugs\u201d","author":"Rannazzisi","year":"2013"},{"issue":"5","key":"10.1016\/j.neuropharm.2022.109220_bib116","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00213-014-3721-0","article-title":"Inhaled vs. oral alprazolam: subjective, behavioral and cognitive effects, and modestly increased abuse potential","volume":"232","author":"Reissig","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"issue":"5\u20136","key":"10.1016\/j.neuropharm.2022.109220_bib117","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/FBP.0b013e328363d163","article-title":"Principles of assessment of abuse liability: US legal framework and regulatory environment","volume":"24","author":"Rocha","year":"2013","journal-title":"Behav. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109220_bib118","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-01811-4","article-title":"Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers","volume":"11","author":"Rootman","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2022.109220_bib119","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF00429362","article-title":"Comparison of a lacebo, N-Dimethyltryptamine, and 6-Hydroxy-N-Dimethyltryptamine in man","volume":"4","author":"Rosenberg","year":"1963","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.neuropharm.2022.109220_bib120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00405570","article-title":"Observations on direct and cross tolerance witH LSD and D-amphetamine in man","volume":"5","author":"Rosenberg","year":"1963","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.neuropharm.2022.109220_bib121","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/BF00413244","article-title":"The effect of N,N-dimethyltryptamine in human subjects tolerant to lysergic acid diethylamide","volume":"5","author":"Rosenberg","year":"1964","journal-title":"Psychopharmacologia"},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109220_bib122","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/09540261.2018.1482261","article-title":"Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress","volume":"30","author":"Ross","year":"2018","journal-title":"Int. Rev. Psychiatr."},{"issue":"12","key":"10.1016\/j.neuropharm.2022.109220_bib123","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109220_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109174","article-title":"Psychedelic-assisted psychotherapy to treat psychiatric and existential distress in life-threatening medical illnesses and palliative care","author":"Ross","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109220_bib125","author":"Sacco","year":"2020","journal-title":"The Schedule I status of marijuana"},{"key":"10.1016\/j.neuropharm.2022.109220_bib126","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1037\/pha0000253","article-title":"Effects of acute and repeated treatment with serotonin 5-HT2A receptor agonist hallucinogens on intracranial self-stimulation in rats","volume":"27","author":"Sakloth","year":"2019","journal-title":"Exp. Clin. Psychopharmacol"},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109220_bib127","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/sj.clpt.6100492","article-title":"Assessing abuse liability during drug development: changing standards and expectations","volume":"83","author":"Schoedel","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109220_bib128","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/cpt.776","article-title":"Psychedelic drugs as therapeutics: no illusions about the challenges","volume":"103","author":"Sellers","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2022.109220_bib129","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.neuropharm.2017.11.029","article-title":"Studies with psychedelic drugs in human volunteers","volume":"142","author":"Sellers","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109220_bib130","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3389\/fpsyt.2019.00138","article-title":"A review of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy","volume":"10","author":"Sessa","year":"2019","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109220_bib131","doi-asserted-by":"crossref","first-page":"896","DOI":"10.3389\/fpsyt.2019.00896","article-title":"Population survey data informing the therapeutic potential of classic and novel phenethylamine, tryptamine, and lysergamide psychedelics","volume":"10","author":"Sexton","year":"2019","journal-title":"Front. Psychiatr."},{"issue":"5","key":"10.1016\/j.neuropharm.2022.109220_bib132","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1161\/HYPERTENSIONAHA.120.16715","article-title":"Association between lifetime classic psychedelic use and hypertension in the past year","volume":"77","author":"Simonsson","year":"2021","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109220_bib133","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-93787-4","article-title":"Associations between lifetime classic psychedelic use and cardiometabolic diseases","volume":"11","author":"Simonsson","year":"2021","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109220_bib134","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/0269881121996863","article-title":"Associations between lifetime classic psychedelic use and markers of physical health","volume":"35","author":"Simonsson","year":"2021","journal-title":"J. Psychopharmacol."},{"issue":"3 Suppl. l","key":"10.1016\/j.neuropharm.2022.109220_bib135","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S0376-8716(03)00096-6","article-title":"Keeping the lid on: a century of drug regulation and control","volume":"70","author":"Spillane","year":"2003","journal-title":"Drug Alcohol Depend."},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2022.109220_bib136","first-page":"121","article-title":"Human psychopharmacology of N,N-dimethyltryptamine","volume":"73","author":"Strassman","year":"1996","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2022.109220_bib137","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40801-020-00223-6","article-title":"The Xyrem\u00ae (sodium oxybate) risk evaluation and mitigation Strategy (REMS) program in the USA: results from 2016 to 2017","volume":"8","author":"Strunc","year":"2021","journal-title":"Drugs Real World Outcomes"},{"key":"10.1016\/j.neuropharm.2022.109220_bib138","series-title":"Key Substance Use and Mental Health Indicators in the United States: Results from the 2020 National Survey on Drug Use and Health (HHS Publication No. PEP21-07-01-003, NSDUH Series H-56)","author":"Substance Abuse and Mental Health Services Administration","year":"2021"},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109220_bib139","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jts.2490090305","article-title":"The Posttraumatic Growth Inventory: measuring the positive legacy of trauma","volume":"9","author":"Tedeschi","year":"1996","journal-title":"J. Trauma Stress"},{"key":"10.1016\/j.neuropharm.2022.109220_bib140","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/ajhp\/zxz065","article-title":"Esketamine nasal spray approved for treatment-resistant depression","volume":"76","author":"Traynor","year":"2019","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.neuropharm.2022.109220_bib141","series-title":"The International Drug Control Conventions","year":"2013"},{"key":"10.1016\/j.neuropharm.2022.109220_bib25","year":"1965"},{"key":"10.1016\/j.neuropharm.2022.109220_bib26","series-title":"Public law no: 114-89. H.R.639 - Improving regulatory transparency for new medical therapies Act 114th Congress (2015-2016)","year":"2015"},{"key":"10.1016\/j.neuropharm.2022.109220_bib145","series-title":"Schedules of Controlled Substances: Placement in Schedule V of Certain FDA-Approved Drugs Containing Cannabidiol; Corresponding Change to Permit Requirements: a Rule by the Drug Enforcement Administration","year":"2018"},{"key":"10.1016\/j.neuropharm.2022.109220_bib148","year":"2022","journal-title":"The Controlled Substances Act."},{"key":"10.1016\/j.neuropharm.2022.109220_bib153","series-title":"Assessment of Abuse Potential of Drugs: Guidance for Industry","year":"2017"},{"key":"10.1016\/j.neuropharm.2022.109220_bib154","series-title":"Advisory Committee Meeting to Discuss New Drug Application 211802 for Oxycodegol. Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory","year":"2020"},{"key":"10.1016\/j.neuropharm.2022.109220_bib155","series-title":"Risk Evaluation and Mitigation Strategies: Modifications and Revisions. Guidance for Industry","year":"2020"},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109220_bib159","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1523\/JNEUROSCI.3822-08.2009","article-title":"Mood influences supraspinal pain processing separately from attention","volume":"29","author":"Villemure","year":"2009","journal-title":"J. Neurosci."},{"issue":"12","key":"10.1016\/j.neuropharm.2022.109220_bib160","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1111\/j.1360-0443.1991.tb01745.x","article-title":"The necessity and utility of abuse liability evaluations in human subjects","volume":"86","author":"Vocci","year":"1991","journal-title":"Br. J. Addict."},{"key":"10.1016\/j.neuropharm.2022.109220_bib161","author":"Volkow"},{"issue":"13","key":"10.1016\/j.neuropharm.2022.109220_bib162","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJMra1507771","article-title":"Opioid abuse in chronic pain--misconceptions and mitigation strategies","volume":"374","author":"Volkow","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2022.109220_bib163","series-title":"Biden-Harris Administration Provides Recommendations to Congress on Reducing Illicit Fentanyl-Related Substances","author":"White House","year":"2021"},{"key":"10.1016\/j.neuropharm.2022.109220_bib164","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00413101","article-title":"Cross tolerance between mescaline and LSD-25, with a comparison of the mescaline and LSD reactions","volume":"3","author":"Wolbach","year":"1962","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.neuropharm.2022.109220_bib165","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/BF00412109","article-title":"Comparison of psilocin with psilocybin, mescaline and LSD-25","volume":"3","author":"Wolbach","year":"1962","journal-title":"Psychopharmacologia"},{"issue":"5","key":"10.1016\/j.neuropharm.2022.109220_bib166","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jamapsychiatry.2020.3672","article-title":"Psychedelics in psychiatry -- keeping the renaissance from going off the rails","volume":"78","author":"Yaden","year":"2021","journal-title":"JAMA Psychiatr."},{"issue":"2\u20133","key":"10.1016\/j.neuropharm.2022.109220_bib167","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0376-8716(86)90004-9","article-title":"Intravenous self-administration of (-)-cathinone and 2-amino-1-(2,5-dimethoxy-4-methyl)phenylpropane in rhesus monkeys","volume":"17","author":"Yanagita","year":"1986","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2022.109220_bib168","unstructured":"Zia, 2022 (In this issue). TBA."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822002799?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822002799?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:20:53Z","timestamp":1758439253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390822002799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":153,"alternative-id":["S0028390822002799"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109220","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109220","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109220"}}